Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.71%
1,092.80
-7.77
-0.71%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.07%
604.74
-0.41
-0.07%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.64%
1,214.80
+19.61
+1.64%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,724.57
-15.34
-0.88%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.14%
639.43
+0.87
+0.14%
—638.56640.21645.32638.69——
SIXR
Staples
SIXR
Staples
SIXR
+0.91%
839.15
+7.58
+0.91%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.06%
215.62
+2.26
+1.06%
—213.36213.36215.79212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.69%
3,179.52
-54.66
-1.69%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.13%
936.91
+1.26
+0.13%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.24%
1,452.77
+3.51
+0.24%
—1,449.261,454.771,462.651,447.95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,365.18
-17.27
-0.72%
—2,382.452,371.192,380.452,362.86——
MOLN:NASDAQ
Molecular Partners AG
$4.28
-1.61%
(-0.070) 1D
Apr 28, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MOLN...
Open
$4.28
High
$4.28
Low
$4.28
Mkt. cap
169.66M
Avg. vol.
4.04K
Volume
832.00
52-wk high
$5.36
52-wk low
$3.36
EPS
-$2.11
Beta
1.03
Shares outstanding
40.38M
No. of employees
134
News stories
From sources across the web
Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
About Molecular Partners AG
CEO-
Employees134
Founded2004
Headquarters-
SectorBiotechnology
Websitemolecularpartners.com
Last report
Mar 12, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-0.36/ (-0.30 est.)CHF
-22.03%miss
Revenue / Estimate
-/ (0.00 est.)CHF
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
11.92M
10.71M
8.33M
8.18M
Cost of revenue
11.92M
10.71M
8.33M
8.18M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.22M
3.99M
3.60M
4.48M
Operating expense
4.22M
3.99M
3.60M
4.48M
Total operating expenses
16.14M
14.70M
11.93M
12.67M
Operating income
-16.14M
-14.70M
-11.93M
-12.67M
Other non operating income
-4.00K
-3.00K
-2.00K
-5.00K
EBT including unusual items
-16.77M
-20.40M
-11.84M
-12.64M
EBT excluding unusual items
-16.77M
-17.78M
-11.72M
-12.69M
Income tax expense
-2.00K
-
-
4.00K
Effective tax rate
0.01%
-
-
-0.03%
Other operating expenses
-
-
-
-
Net income
-16.77M
-20.40M
-11.84M
-12.65M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.56
-0.33
-0.36
Interest and investment income
502.00K
420.00K
366.00K
234.00K
Interest expense
-5.00K
-4.00K
-3.00K
-6.00K
Net interest expenses
497.00K
416.00K
363.00K
228.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-15.59M
-14.15M
-11.40M
-12.44M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer